Illumina is proud to offer the verifi® prenatal test—a non-invasive prenatal test that detects multiple fetal chromosomal aneuploidies using a single maternal blood draw. If you have ever wanted safer, simpler test results or wished to screen at 10 weeks instead of waiting, now you can order the verifi® prenatal test.
Swift acceptance of the verifi® prenatal test has made a world of difference to high-risk patients across the country:
As sequencing technology rapidly evolves, our research team has analyzed and implemented several changes to the testing procedure that yield enhanced test performance.
|N||Observed Sensitivity||95% CI||Observed Specificity||95% CI|
|Both “Aneuploidy Detected” and “Aneuploidy Suspected (Borderline Value)” results were included for performance calculation.|
|MX||508||95.0% (19/20)||75.1-99.9||99.0% (483/488)||97.6-99.7|
The verifi® test now includes an option for the most common sex aneuploidies, providing information previously known only through invasive results.
|N||Sensitivity||95% CI||Specificity||95% CI||Accuracy||95% CI|
|XX||508||97.6% (243/249)||94.8-99.1||99.2% (257/259)||97.2-99.9||98.4%||96.9-99.3|
|XY||508||99.1% (227/229)||96.9-99.9||98.9% (276/279)||96.9-99.8||99.0%||97.7-99.7|
|Limited data of these more rare aneuploidies preclude performance calculations.|
This screening test is intended for patients at 10 weeks or greater gestation with singleton pregnancies who meet any of the following criteria:
Our Client Services group is on site and readily available along with certified genetic counselors to provide knowledgeable, timely support.
Call Illumina at: (855) 266-6563